Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWegovy can indirectly make you feel thirsty, though thirst itself is not listed as a direct side effect in the licensed prescribing information. The more likely cause is the nausea, vomiting, or diarrhoea that semaglutide commonly produces, particularly in the early weeks, which can reduce your fluid intake or increase fluid loss and leave you noticeably dehydrated. Staying well-hydrated on treatment matters more than most people realise. These are prescription-only medicines, and a clinician assesses your suitability before any treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The STEP 1 trial, which studied semaglutide 2.4mg in nearly 2,000 adults over 68 weeks and was published in the New England Journal of Medicine, recorded nausea in roughly 44% of participants on semaglutide versus 16% on placebo. Vomiting and diarrhoea each occurred in around a fifth of participants on the active treatment. These figures matter here because every episode of vomiting or loose stool carries fluid and electrolytes out of the body. The thirst you feel on Wegovy is usually your body's ordinary response to that deficit, not a signal that something unusual is happening at a pharmacological level.
There is a common assumption that GLP-1 medicines directly stimulate the thirst mechanism. The current evidence does not support that. Semaglutide slows gastric emptying and reduces appetite through GLP-1 receptor pathways, and some people eat and drink less overall, compounding a mild fluid shortfall. If you want a closer look at why semaglutide causes thirst and what the research says about the mechanism, that page goes into more detail. Knowing the actual cause makes it easier to manage.
Increased thirst can also be an early sign of raised blood glucose in people with or at risk of type 2 diabetes, worth raising with your prescriber if you are in that group, since semaglutide is used across both diabetes and weight-management indications.
The NHS guidance on semaglutide notes that severe vomiting or diarrhoea can lead to dehydration, and that dehydration in turn can cause kidney problems. This is not a reason to be alarmed, it is a reason to take fluid intake seriously from day one of treatment. Most people on Wegovy never experience anything beyond mild nausea, especially as the body adjusts over the first few weeks at each dose level.
The signs that dehydration has gone further than minor thirst include a significant drop in the frequency of urination, dark urine, dizziness when standing, and persistent dry mouth that does not improve with drinking. If you reach that point, the right move is to contact a healthcare professional rather than push through. If you are also taking medicines that can affect the kidneys (some blood pressure drugs, for instance) your prescriber needs to know, because the combination raises the risk.
One thing that does not help: dramatically cutting food intake on the grounds that Wegovy has suppressed appetite so strongly. Eating too little means drinking too little, and the ripple effects on hydration are cumulative. Protein and fibre from regular small meals, alongside steady water intake through the day, make a real difference to how tolerable the early weeks feel. Questions about managing thirst and fluid balance on Wegovy specifically are worth raising at your clinical review.
Plain water, spread through the day rather than gulped in large amounts at once, is usually the simplest fix. Large volumes drunk quickly can provoke nausea in people whose gastric emptying is already slowed by semaglutide, so small, regular sips work better for most people. Herbal teas and diluted squash count. Caffeine and alcohol, both of which have a mild diuretic effect, are worth limiting when GI symptoms are active.
If nausea is the reason you are not drinking enough, eating smaller, blander meals (lower in fat and sugar) can reduce the severity. Some people find that sipping fluid during a meal is easier than drinking between meals at the start of treatment. These are adjustments, not instructions; what suits you is something to work through with your prescriber or a dietitian.
The wider picture of how semaglutide affects your body goes beyond thirst. Some people also notice changes in temperature regulation, there is a separate explanation of whether Wegovy makes you feel hot, and a parallel page on feeling cold on treatment, both of which touch on how reduced food intake changes the body's heat production. Worth a read if those symptoms have appeared alongside the thirst.
For a broader overview of what semaglutide is and how it works as a treatment, the semaglutide overview covers the mechanism in more depth. If you are specifically looking into Rohm semaglutide and how that particular formulation compares, there is a dedicated page covering that. And if you are weighing up whether Wegovy is the right option for you, our weight-loss treatments page is the place to speak to our prescribers and get a same-day clinical review at no cost.
Contact a doctor or pharmacist promptly if: thirst is severe and not relieved by drinking; you have not urinated in several hours; you feel faint or very dizzy; you have persistent vomiting or diarrhoea lasting more than a day or two; or you develop severe stomach pain that spreads to your back, with or without vomiting. That last combination is the key symptom pattern flagged in MHRA safety communications regarding acute pancreatitis associated with GLP-1 medicines, uncommon, but serious enough to warrant same-day medical attention rather than watchful waiting.
If you suspect a side effect from Wegovy, you can report it directly to the MHRA via the Yellow Card scheme. Patient reports help regulators track emerging patterns and refine the safety picture for everyone on these medicines.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.